Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
RION Completes Enrollment for Phase 2 Diabetic Foot Ulcer Trial with PEP™
Details : PEP is a proprietary, lyophilized exosome-based powder derived from human platelets, engineered to enhance the body’s natural healing mechanisms, currently being investigated for diabetic foot ulcers.
Product Name : PEP
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
January 13, 2025
Lead Product(s) : Purified Exosome Product
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RION Initiates Phase 1b Study of Purified Exosome Product™ for Knee Osteoarthritis
Details : RION's Purified Exosome Product (PEP) is a shelf stable product in a lyophilized powder derived from human platelets that contains stabilized platelet-derived regenerative exosomes.
Product Name : PEP
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 10, 2024
Lead Product(s) : Purified Exosome Product
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ventus Initiates Clinical Testing of VENT-03, an Orally Administered cGAS Inhibitor
Details : Purified Exosome Product, designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells, is being investigated for diabetic foot ulcer.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
May 07, 2024
LOOKING FOR A SUPPLIER?
Reset All
